Changchun High & New Tech (000661.CH) - Logic Change?
The article analyzed Changchun High & New Tech in terms of its 2021/1H financial results,media exposure of growth hormone abuse, possibility of...
179 Views
Everest Medicines (1952.HK) - The Commercialization Prospect Has Reshaped
After the BLA submission of Trodelvy, the commercialization prospect of Everest Medicines has reshaped. This article mainly analyzed the business...
251 Views
I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ101
As I-MAB has come to a key phase from R&D to commercialization, this article analyzed both the strength and the concerns for its core products...
218 Views
Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma
This article mainly analyzed Innovent in terms of its current listed products (Sintilimab, Bevacizumab, Adalimumab and Rituximab), its pipeline,...
398 Views
I-Mab Placement - Heading in the Right Direction
A group of shareholders plans to raise around US$200m via selling a 4.6% stake in I-Mab (IMAB US). We have previously covered the IPO as well.
233 Views